Yesterday the Canadian Government’s Task Force on Marijuana released a report for recommendations about the legalization of cannabis in Canada.
The full report entitled A FRAMEWORK FOR THE LEGALIZATION AND REGULATION OF CANNABIS IN CANADA everything from sales and marketing, to taxation to public education, production and distribution.
Where does the potential legalization of cannabis leave patients, who are trying to access cannabis for medical purposes?
Chapter 5 of the report covers this topic and makes some broad recommendations for the program and patients. In general, the task force reached a consensus that there is a need for more research aimed at understanding, validating and approving cannabis-based medicines.
The Task Force also recommends that the federal government:
- Maintain a separate medical access framework to support patients
- Monitor and evaluate patients’ reasonable access to cannabis for medical purposes through the implementation of the new system, with action as required to ensure that the market provides reasonable affordability and availability and that regulations provide authority for measures that may be needed to address access issues
- Review the role of designated persons under the ACMPR with the objective of eliminating this category of producer
- Apply the same tax system for medical and non-medical cannabis products
- Promote and support pre-clinical and clinical research on the use of cannabis and cannabinoids for medical purposes, with the aim of facilitating submissions of cannabis-based products for market authorization as drugs
- Support the development and dissemination of information and tools for the medical community and patients on the appropriate use of cannabis for medical purposes
- Evaluate the medical access framework in five years